We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+14.95%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.78B
AUM Growth
-$802M
Cap. Flow
-$1.61B
Cap. Flow %
-18.35%
Top 10 Hldgs %
33.27%
Holding
157
New
20
Increased
27
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$131M
2
MRK icon
Merck
MRK
+$97.5M
3
EW icon
Edwards Lifesciences
EW
+$97.4M
4
AGN.PRA
Allergan plc
AGN.PRA
+$76.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$72.9M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$213M
2
BMY icon
Bristol-Myers Squibb
BMY
+$184M
3
ABBV icon
AbbVie
ABBV
+$152M
4
BSX icon
Boston Scientific
BSX
+$141M
5
AGN
Allergan plc
AGN
+$138M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$130B
$118M 1.34%
2,187,400
-2,868,200
-57% -$184M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$11.9B
$107M 1.21%
1,151,900
-366,600
-24% -$34.5M
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$106M 1.21%
13,107,200
+1,425,600
+12% +$12.1M
ESRX
29
DELISTED
Express Scripts Holding Company
ESRX
$102M 1.17%
1,451,900
-246,700
-15% -$18.4M
JNJ icon
30
Johnson & Johnson
JNJ
$644B
$101M 1.15%
858,000
+80,400
+10% +$9.75M
HCA icon
31
HCA Healthcare
HCA
$91.9B
$99.2M 1.13%
1,312,200
-2,786,100
-68% -$213M
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
$95.7M 1.09%
14,179,900
+3,206,000
+29% +$12.4M
ZBH icon
33
Zimmer Biomet
ZBH
$18.6B
$93.3M 1.06%
739,025
-149,350
-17% -$18.5M
NBIX icon
34
Neurocrine Biosciences
NBIX
$18.2B
$91.9M 1.05%
1,815,474
– –
ILMN icon
35
Illumina
ILMN
$29B
$90M 1.03%
509,374
-360,520
-41% -$57.7M
IPXL
36
DELISTED
Impax Laboratories, Inc.
IPXL
$89.8M 1.02%
3,787,500
-2,099,200
-36% -$56.4M
CRVS icon
37
Corvus Pharmaceuticals
CRVS
$1.1B
$88.5M 1.01%
5,379,349
– –
UNH icon
38
UnitedHealth
UNH
$385B
$85.7M 0.98%
611,800
-596,400
-49% -$83.5M
BOLD
39
DELISTED
Audentes Therapeutics, Inc
BOLD
$85.5M 0.97%
+4,801,638
New +$72.9M
TEVA icon
40
Teva Pharmaceuticals
TEVA
$39.1B
$84.3M 0.96%
1,831,400
-928,400
-34% -$48.4M
GKOS icon
41
Glaukos
GKOS
$9.17B
$82.3M 0.94%
2,180,000
-717,938
-25% -$23.8M
MNK
42
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$81.7M 0.93%
1,170,200
-138,800
-11% -$10M
BLUE
43
DELISTED
bluebird bio
BLUE
$80.4M 0.92%
91,544
– –
EXEL icon
44
Exelixis
EXEL
$14B
$79.4M 0.9%
+6,206,300
New +$67.1M
INSM icon
45
Insmed
INSM
$22.6B
$76.2M 0.87%
5,251,100
+1,092,500
+26% +$13.7M
HUM icon
46
Humana
HUM
$43.6B
$74.9M 0.85%
423,500
+83,800
+25% +$14.5M
EGRX
47
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$72.5M 0.83%
1,036,100
– –
AGN.PRA
48
DELISTED
Allergan plc
AGN.PRA
$72.5M 0.83%
+88,200
New +$76.2M
MDT icon
49
Medtronic
MDT
$113B
$66.2M 0.75%
766,600
+100,301
+15% +$8.74M
INSY
50
DELISTED
Insys Therapeutics, Inc.
INSY
$64.9M 0.74%
5,502,240
+814,000
+17% +$12.4M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2016 Portfolio in Review

As of Q3 2016, OrbiMed held 157 positions worth $8.78B, down 8.4% from $9.58B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed withdrew a net $1.61B in Q3 2016, closing 17 positions and reducing 40 holdings. Its most notable exit was RELYPSA INC COM, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Allergan plc worth $72.5M.

  • OrbiMed's largest Q3 2016 buy was Allergan plc: 88,200 shares worth $72.5M.
  • OrbiMed added most to Shire pic in Q3 2016, an estimated $131M increase.
  • OrbiMed's biggest Q3 2016 reduction was HCA Healthcare, cutting an estimated $213M.
  • OrbiMed fully exited RELYPSA INC COM in Q3 2016, selling an estimated $137M.
  • OrbiMed's ten largest holdings make up 33% of its $8.78B portfolio in Q3 2016.
  • OrbiMed opened 20 new positions and closed 17 in Q3 2016.
  • OrbiMed's portfolio value fell 8.4% quarter-over-quarter to $8.78B.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.